The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Eloxatine     (1R,2R)-cyclohexane-1,2- diamine;...

Synonyms: GSOX, L-platin, l-OHP, ACT-078, S1224_Selleck, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of oxaliplatin


Psychiatry related information on oxaliplatin

  • The most effective current regimen for adjuvant treatment of surgically resected stage III colon cancer is the FOLFOX regimen of oxaliplatin, 5-FU and LV for 12 weeks, with a proportional risk reduction of 45% compared with approximately 36% for 5-FU/LV regimens [5].

High impact information on oxaliplatin


Chemical compound and disease context of oxaliplatin


Biological context of oxaliplatin


Anatomical context of oxaliplatin

  • Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling [19].
  • When oxaliplatin was incubated in whole blood (5, 10, and 20 micrograms/ml), the erythrocytes took up 37.1 +/- 2.1% of the total platinum in 2 h (maximum uptake) which was not exchangeable into plasma [17].
  • CONCLUSION: Considering the particularly unfavorable prognostic characteristics of this patient population compared with patients from previous trials for new drugs in germ cell cancer, eg, paclitaxel and gemcitabine, a 13% overall response rate and a 19% response rate in the group treated with oxaliplatin 130 mg/m(2) seems to be of interest [10].
  • Acute oxaliplatin-induced peripheral nerve hyperexcitability [18].
  • Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer [12].

Associations of oxaliplatin with other chemical compounds


Gene context of oxaliplatin


Analytical, diagnostic and therapeutic context of oxaliplatin


  1. Adjuvant therapy of colon cancer. Macdonald, J.S. CA: a cancer journal for clinicians. (1999) [Pubmed]
  2. FDA evaluating oxaliplatin for advanced colorectal cancer treatment. Baldwin, J. J. Natl. Cancer Inst. (2002) [Pubmed]
  3. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gallmeier, E., Calhoun, E.S., Rago, C., Brody, J.R., Cunningham, S.C., Hucl, T., Gorospe, M., Kohli, M., Lengauer, C., Kern, S.E. Gastroenterology (2006) [Pubmed]
  4. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Moufarij, M.A., Sampath, D., Keating, M.J., Plunkett, W. Blood (2006) [Pubmed]
  5. Adjuvant therapy for colon cancer 2005: new options in the twenty-first century. Leichman, C.G. Surg. Oncol. Clin. N. Am. (2006) [Pubmed]
  6. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Stoehlmacher, J., Park, D.J., Zhang, W., Groshen, S., Tsao-Wei, D.D., Yu, M.C., Lenz, H.J. J. Natl. Cancer Inst. (2002) [Pubmed]
  7. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. Caussanel, J.P., Lévi, F., Brienza, S., Misset, J.L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., Mathé, G. J. Natl. Cancer Inst. (1990) [Pubmed]
  8. Apoptosis regulation in tetraploid cancer cells. Castedo, M., Coquelle, A., Vivet, S., Vitale, I., Kauffmann, A., Dessen, P., Pequignot, M.O., Casares, N., Valent, A., Mouhamad, S., Schmitt, E., Modjtahedi, N., Vainchenker, W., Zitvogel, L., Lazar, V., Garrido, C., Kroemer, G. EMBO J. (2006) [Pubmed]
  9. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Boyer, J., Allen, W.L., McLean, E.G., Wilson, P.M., McCulla, A., Moore, S., Longley, D.B., Caldas, C., Johnston, P.G. Cancer Res. (2006) [Pubmed]
  10. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. Kollmannsberger, C., Rick, O., Derigs, H.G., Schleucher, N., Schöffski, P., Beyer, J., Schoch, R., Sayer, H.G., Gerl, A., Kuczyk, M., Spott, C., Kanz, L., Bokemeyer, C. J. Clin. Oncol. (2002) [Pubmed]
  11. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., Schöffski, P., Sobrero, A., Van Cutsem, E., Díaz-Rubio, E. J. Clin. Oncol. (2004) [Pubmed]
  12. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Scheithauer, W., Kornek, G.V., Raderer, M., Valencak, J., Weinländer, G., Hejna, M., Haider, K., Kwasny, W., Depisch, D. J. Clin. Oncol. (1999) [Pubmed]
  13. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. Louvet, C., André, T., Lledo, G., Hammel, P., Bleiberg, H., Bouleuc, C., Gamelin, E., Flesch, M., Cvitkovic, E., de Gramont, A. J. Clin. Oncol. (2002) [Pubmed]
  14. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. Scheithauer, W., Kornek, G.V., Raderer, M., Ulrich-Pur, H., Fiebiger, W., Gedlicka, C., Schüll, B., Brugger, S., Schneeweiss, B., Lang, F., Lenauer, A., Depisch, D. J. Clin. Oncol. (2002) [Pubmed]
  15. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. Wasserman, E., Cuvier, C., Lokiec, F., Goldwasser, F., Kalla, S., Méry-Mignard, D., Ouldkaci, M., Besmaine, A., Dupont-André, G., Mahjoubi, M., Marty, M., Misset, J.L., Cvitkovic, E. J. Clin. Oncol. (1999) [Pubmed]
  16. KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Smakman, N., van den Wollenberg, D.J., Elias, S.G., Sasazuki, T., Shirasawa, S., Hoeben, R.C., Borel Rinkes, I.H., Kranenburg, O. Cancer Res. (2006) [Pubmed]
  17. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Pendyala, L., Creaven, P.J. Cancer Res. (1993) [Pubmed]
  18. Acute oxaliplatin-induced peripheral nerve hyperexcitability. Wilson, R.H., Lehky, T., Thomas, R.R., Quinn, M.G., Floeter, M.K., Grem, J.L. J. Clin. Oncol. (2002) [Pubmed]
  19. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Rakitina, T.V., Vasilevskaya, I.A., O'Dwyer, P.J. Cancer Res. (2003) [Pubmed]
  20. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. Rothenberg, M.L., Meropol, N.J., Poplin, E.A., Van Cutsem, E., Wadler, S. J. Clin. Oncol. (2001) [Pubmed]
  21. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. Fizazi, K., Ducreux, M., Ruffié, P., Bonnay, M., Daniel, C., Soria, J.C., Hill, C., Fandi, A., Poterre, M., Smith, M., Armand, J.P. J. Clin. Oncol. (2000) [Pubmed]
  22. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Koivusalo, R., Krausz, E., Ruotsalainen, P., Helenius, H., Hietanen, S. Cancer Res. (2002) [Pubmed]
  23. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. Freyer, G., Bossard, N., Romestaing, P., Mornex, F., Chapet, O., Trillet-Lenoir, V., Gérard, J.P. J. Clin. Oncol. (2001) [Pubmed]
  24. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Fink, D., Zheng, H., Nebel, S., Norris, P.S., Aebi, S., Lin, T.P., Nehmé, A., Christen, R.D., Haas, M., MacLeod, C.L., Howell, S.B. Cancer Res. (1997) [Pubmed]
  25. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Boyer, J., McLean, E.G., Aroori, S., Wilson, P., McCulla, A., Carey, P.D., Longley, D.B., Johnston, P.G. Clin. Cancer Res. (2004) [Pubmed]
  26. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Lin, X., Okuda, T., Holzer, A., Howell, S.B. Mol. Pharmacol. (2002) [Pubmed]
  27. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Balin-Gauthier, D., Delord, J.P., Rochaix, P., Mallard, V., Thomas, F., Hennebelle, I., Bugat, R., Canal, P., Allal, C. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  28. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. Peters, G.J., Smorenburg, C.H., Van Groeningen, C.J. Journal of chemotherapy (Florence, Italy) (2004) [Pubmed]
  29. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. Rödel, C., Grabenbauer, G.G., Papadopoulos, T., Hohenberger, W., Schmoll, H.J., Sauer, R. J. Clin. Oncol. (2003) [Pubmed]
  30. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Kemeny, N., Jarnagin, W., Paty, P., Gönen, M., Schwartz, L., Morse, M., Leonard, G., D'Angelica, M., DeMatteo, R., Blumgart, L., Fong, Y. J. Clin. Oncol. (2005) [Pubmed]
  31. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., Papamichael, D., Le Bail, N., Louvet, C., Hendler, D., de Braud, F., Wilson, C., Morvan, F., Bonetti, A. J. Clin. Oncol. (2000) [Pubmed]
  32. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Ramanathan, R.K., Clark, J.W., Kemeny, N.E., Lenz, H.J., Gococo, K.O., Haller, D.G., Mitchell, E.P., Kardinal, C.G. J. Clin. Oncol. (2003) [Pubmed]
WikiGenes - Universities